Sutro Biopharma, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
STRO chart
What traders are saying about $STRO
Latest postsSutro Biopharma, Inc. news
- Sutro Biopharma, Inc. Estimates – NASDAQ:STRO
TradingView ·
- Sutro Biopharma (NasdaqGM:STRO) Stock Forecast & Analyst Predictions
Simply Wall Street ·
- Sutro Biopharma doses first patient in STRO-006 trial
TipRanks ·
- Sutro Biopharma doses first patient in STRO-006 phase 1 trial
Investing.com ·
- Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Yahoo Finance ·
- Sutro's second antibody-linked cancer drug entered human testing in less than a year.
Stock Titan ·
- Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Yahoo Finance ·
- Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Yahoo Finance ·
- STRO Stock Plummets 15% — What Drove The Selloff?
stocktwits.com ·
- Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Yahoo Finance ·
- Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance ·
- Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
247wallst.com ·
Sutro Biopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M |
| Net income | -$191.0M | -$227.0M | -$107.0M | -$119.2M |
| Diluted EPS | $-22.49 | $-29.40 | $-1.78 | $-2.35 |
| Total assets (year end) | $173.8M | $387.2M | $470.7M | $406.9M |
| Cash and equivalents (year end) | $58.1M | $190.3M | $69.3M | $47.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Sutro Biopharma, Inc.
- Ticker
- STRO (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- SEC CIK
- 1382101
- Former names
- SUTRO BIOPHARMA INC, Fundamental Applied Biology Inc
Frequently asked questions
What exchange is Sutro Biopharma, Inc. listed on?
Sutro Biopharma, Inc. trades on the Nasdaq under the ticker symbol STRO.
What industry is Sutro Biopharma, Inc. in?
Sutro Biopharma, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Sutro Biopharma, Inc. headquartered?
Sutro Biopharma, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Sutro Biopharma, Inc.'s fiscal year end?
Sutro Biopharma, Inc.'s fiscal year ends on December 31.
How much revenue did Sutro Biopharma, Inc. report?
Sutro Biopharma, Inc. reported $102.5M in revenue for calendar year 2025, according to its SEC filings.